Skip to main content

Search

Reset all filters
109 Result(s)
Sort by

Science Stories

Science Stories

Science and Innovation - Human Health Innovation - Science Stories
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
Parasiticides

Parasiticides

Science and Innovation - Animal Health Innovation - Parasiticides
Animal Health Partnering

Animal Health Partnering

Description Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team
Fostering Science

Fostering Science

Science and Innovation - Human Health Innovation - Fostering Science
Therapeutics

Therapeutics

Science and Innovation - Animal Health Innovation - Therapeutics
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Life forward - Boehringer Ingelheim unveils its evolved company brand

Life forward - Boehringer Ingelheim unveils its evolved company brand

Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Victor Emenike

Victor Emenike

Victor Emenike is a data scientist in operations, specifically in the launch and innovation organization, feels valued and supported in new ideas.
Science Focus

Science Focus

Science and Innovation - Human Health Innovation - Science Focus